Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 8/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.32 |
| ▸ | LCK | P06239 | 3/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22125159 | 0.95 | PTK6 (0.41) | PTK6AURKBLCKTTKJAK2 | |
| SCHEMBL30385656 | 0.95 | PTK6 (0.41) | PTK6AURKBLCKTTKJAK2 | |
| Trifluoroacetic Acid SCHEMBL30178075 | 0.86 | PTK6 (0.37) | PTK6AURKBLCKTTKJAK2 | |
| Trifluoroacetic Acid SCHEMBL30177638 | 0.86 | PTK6 (0.38) | PTK6AURKBLCKTTKJAK2 | |
| Formic Acid SCHEMBL30386621 | 0.86 | PTK6 (0.35) | PTK6AURKBLCK | |
| SCHEMBL24870930 | 0.86 | PTK2 (0.38) | PTK6TTKJAK2JAK1PTK2 | |
| SCHEMBL30172036 | 0.86 | PTK2 (0.38) | PTK6TTKJAK2JAK1PTK2 | |
| SCHEMBL24112463 | 0.86 | PTK6 (0.36) | PTK6AURKBLCK | |
| Trifluoroacetic Acid SCHEMBL30177687 | 0.85 | PTK6 (0.35) | PTK6AURKBLCKJAK2JAK1 | |
| SCHEMBL25176078 | 0.84 | PTK6 (0.42) | PTK6AURKBLCKTTKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4161931-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| CN-115916784-A | Novel imidazopyrazine derivatives | 豪夫迈·罗氏有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | PTK6 2201/4885AURKB 3265/4885LCK 2427/4885 |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | IKZF3, RRP15, IK | PTK6 925/4885AURKB 4161/4885LCK 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.